Patents by Inventor Howard M. Goodman
Howard M. Goodman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6841722Abstract: Disclosed is a Arabidopsis sse1 gene, which is responsible for protein and oil body biogenesis. The invention further provides methods for using the disclosed gene for modifying the components of plant storage reserve materials.Type: GrantFiled: April 7, 2000Date of Patent: January 11, 2005Assignee: The General Hospital CorporationInventors: Yun Lin, Lin Sun, Long V. Nguyen, Howard M. Goodman
-
Patent number: 6355411Abstract: Disclosed are bacterial virulence polypeptides and nucleic acid sequences (e.g., DNA) encoding such polypeptides, and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such polypeptides to screen for antibacterial or bacteriostatic compounds.Type: GrantFiled: November 25, 1998Date of Patent: March 12, 2002Assignee: The General Hospital CorporationInventors: Frederick Ausubel, Howard M. Goodman, Laurence G. Rahme, Shalina Mahajan-Miklos, Man-Wah Tan, Hui Cao, Eliana Drenkard, John Tsongalis
-
Patent number: 6248937Abstract: Identification, cloning and sequencing of the Arabidopsis ABI4 gene involved in seed response to abscisic acid (ABA) that regulates production of seed nutrient reserves and desiccation protectants. A method for regulating seed development, viability, stress-tolerance and nutrient reserves.Type: GrantFiled: April 27, 1999Date of Patent: June 19, 2001Assignee: The Regents of the University of CaliforniaInventors: Ruth R. Finkelstein, Tim Lynch, Howard M. Goodman, Ming-Li Wang
-
Patent number: 6071730Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: June 6, 2000Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 6015794Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 6, 1995Date of Patent: January 18, 2000Assignee: The General Hospital CorporationInventors: James Haseloff, Howard M. Goodman
-
Patent number: 6013472Abstract: The invention relates to the DNA and protein encoded by the GA4 locus. This protein is believed to be a member of the family of enzymes involved in the biosynthesis of the gibberellin family (GA) of plant growth hormones which promote various growth and developmental processes in higher plants, such as seed germination, stem elongation, flowering and fruiting. More specifically, the protein encoded by the GA4 locus is an hydroxylase. The invention also relates to vectors containing the DNA and the expression of the protein encoded by the DNA of the invention in a host cell. Additional aspects of the invention are drawn to host cells transformed with the DNA or antisense sequence of the invention, the use of such host cells for the maintenance, or expression or inhibition of expression of the DNA of the invention and to transgenic plants containing DNA of the invention. Finally, the invention also relates to the use of the protein encoded by the GA4 locus to alter aspects of plant growth.Type: GrantFiled: January 17, 1997Date of Patent: January 11, 2000Assignee: The General Hospital CorporationInventors: Hui-Hwa Chiang, Howard M. Goodman
-
Patent number: 6010904Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: January 4, 2000Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5925807Abstract: The invention relates to the DNA and protein encoded by the GA4 locus. This protein is believed to be a member of the family of enzymes involved in the biosynthesis of the gibberellin family (GA) of plant growth hormones which promote various growth and developmental processes in higher plants, such as seed germination, stem elongation, flowering and fruiting. More specifically, the protein encoded by the GA4 locus is an hydroxylase. The invention also relates to vectors containing the DNA and the expression of the protein encoded by the DNA of the invention in a host cell. Additional aspects of the invention are drawn to host cells transformed with the DNA or antisense sequence of the invention, the use of such host cells for the maintenance, or expression or inhibition of expression of the DNA of the invention and to transgenic plants containing DNA of the invention. Finally, the invention also relates to the use of the protein encoded by the GA4 locus to alter aspects of plant growth.Type: GrantFiled: March 25, 1997Date of Patent: July 20, 1999Assignee: General Hospital CorporationInventors: Hui-Hwa Chiang, Howard M. Goodman
-
Patent number: 5882907Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: March 16, 1999Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5874414Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.Type: GrantFiled: November 17, 1993Date of Patent: February 23, 1999Assignee: The General Hospital CorporationInventors: James Haseloff, Howard M. Goodman
-
Patent number: 5866384Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: February 2, 1999Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5866779Abstract: The present invention concerns the cloning and sequencing of DNA corresponding to the GA1 locus of A. thaliana which encodes ent-kaurene synthetase, to vectors containing said DNA, to vectors capable of expressing said DNA, and to hosts transformed with said vectors. The invention further concerns the use of the GA1 gene, and regulatory regions thereof, in the generation of chimeric and transgenic plants.Type: GrantFiled: October 20, 1994Date of Patent: February 2, 1999Assignee: The General Hospital CorporationInventors: Tai-Ping Sun, Howard M. Goodman, Frederick M. Ausubel
-
Patent number: 5863774Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: January 26, 1999Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5859346Abstract: Purified DNA encoding crucifer AFT proteins and chimeric transcriptional activator proteins from such DNA are disclosed. Such proteins are also involved in plant defense mechanisms by interacting with proteins involved in protecting plants from pathogens. The recombinant polypeptides and fragments are useful in methods of modulating plant gene expression.Type: GrantFiled: November 14, 1996Date of Patent: January 12, 1999Assignee: The General Hospital CorporationInventors: Hong Zhang, Howard M. Goodman
-
Patent number: 5849548Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: December 15, 1998Assignees: The General Hospital Corporation, The President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5641673Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are base a upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: December 23, 1993Date of Patent: June 24, 1997Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5623054Abstract: Purified DNA encoding crucifer AFT proteins and chimeric transcriptional activator proteins from such DNA are disclosed. Such proteins are also involved in plant defense mechanisms by interacting with proteins involved in protecting plants from pathogens. The recombinant polypeptides and fragments are useful in methods of modulating plant gene expression.Type: GrantFiled: June 23, 1994Date of Patent: April 22, 1997Assignee: The General Hospital CorporationInventors: Hong Zhang, Howard M. Goodman
-
Patent number: 5436139Abstract: The present invention is directed to an expression vector containing DNA which encodes recombinant full-length hepatitis B surface antigen protein wherein said vector is free of DNA encoding hepatitis B core antigen protein in a microorganism.Type: GrantFiled: July 8, 1993Date of Patent: July 25, 1995Assignee: The Regents of the University of CaliforniaInventors: William J. Rutter, Howard M. Goodman
-
Patent number: 5196194Abstract: Recombinant full-length Hepatitis B surface antigen protein is disclosed. This protein is useful in vaccines for the prevention of Hepatitis B infection.Type: GrantFiled: December 7, 1984Date of Patent: March 23, 1993Assignee: The Regents of the University of CaliforniaInventors: William J. Rutter, Howard M. Goodman
-
Patent number: 5145782Abstract: A DNA expression vector is described which is derived from the highly efficient trp operon. The expression vector provides for the direct expression of an inserted gene or cDNA. Using the expression vector described herein, it is possible to obtain the protein coded by the gene or cDNA directly and not as a fusion protein. The expression vector comprises the promoter, operator and leader ribosomal binding site of the trp operon.Type: GrantFiled: November 17, 1987Date of Patent: September 8, 1992Assignee: The Regents of the University of CaliforniaInventors: Robert A. Hallewell, Jeffrey C. Edman, William J. Rutter, Howard M. Goodman